3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
6
Head & Neck
4
Gynecologic
2
Gastrointestinal
2
Other hematologic neoplasm
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
1
Melanoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Interventions
Nivolumab
168
Ipilimumab
152
pembrolizumab
143
Cyclophosphamide
126
Interleukin-2
70
aldesleukin
69
fludarabine phosphate
68
Radiotherapy
67
Biopsy
53
Temozolomide
48
Blood Specimen Collection
45
Peripheral Blood Stem Cell Transplantation
44
fludarabine
43
Radiosurgery
40
trametinib
38
Vemurafenib
36
dabrafenib
33
sargramostim
32
Bevacizumab
31
Aminolevulinic Acid
31
Magnetic Resonance Spectroscopy
30
Mycophenolic Acid
29
Specimen Handling
28
Whole-Body Irradiation
27
Photochemotherapy
26
Imiquimod
26
CTLA-4 Antigen
26
Busulfan
26
Tacrolimus
25
Surveys and Questionnaires
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Nicotine Replacement Therapy
×
Dermatologic
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled